Abstract Cyslabdan produced by Streptomyces sp. K04-0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.015 mg/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to b-lactam antibiotics. Furthermore, among b -lactam antibiotics, the activity of carbapenems was most remarkably poteintiated by cyslabdan.
Introduction
During our screening for potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA) from microbial metabolites, cyslabdan ( Fig. 1) was isolated from the culture broth of Streptomyces sp. K04-0144. The compound has a labdane-type diterpene skeleton connecting with an N-acetylcysteine via thioether linkage [1] . In this study, the biological activities of cyslabdan including potentiation of imipenem activity against MRSA are described.
Materials and Methods

Materials
The following materials were purchased from commercial sources: Cloxacillin (ICN Biomedicals), ampicillin (Wako), cefalexin (Wako), cefazolin (Wako), ciprofloxacin (Wako), vancomycin (Wako), tetracycline (Wako), biapenem (Meiji Seika), streptomycin (Meiji Seika), meropenem (Sumitomo Pharmaceuticals), panipenem (Sankyo), penicillin G (Sigma), cefotaxime (Sigma), cefmetazole (Sigma), and
Assay for Potentiating Activity of Typical Antibiotics against MRSA by Cyslabdan
Potentiation of anti-MRSA activity of imipenem or other antibiotics in combination with cyslabdan was studied by two methods. 1) Paper disk method: MRSA K24 was cultured in Mueller-Hinton broth (MHB, Difco) at 37°C for 20 hours and adjusted to 1ϫ10 8 CFU/ml. The inoculum (100 m l) was spread on the Mueller-Hinton agar (MHA, Difco) in a plate (10ϫ14 cm, Eiken Kizai) containing MHB and 1.5% of agar (Shimizu Shokuhin) with or without imipenem (10 mg/ml), whose concentration has no effect on growth of MRSA. Paper disks (6 mm i.d., Advantec) containing various amounts of a sample were placed on the MHA plate and incubated at 37°C for 20 hours. Anti-MRSA activity was expressed as the diameter (mm) of the inhibitory zone on the MHA plate. 2) Liquid microdilution method [2] ; After MHB (85 ml) was added to each well of a 96-well microplate (Corning), cyslabdan dissolved in H 2 O (5.0 ml) was added to the final concentration of 10 mg/ml. Then imipenem, or other antibiotics dissolved in distilled water (5.0 m l) were added to each well to a final concentration of 0.15 to 1,024 m g/ml. Finally, MRSA (5.0 m l) was added at a concentration of 1ϫ10 7 CFU/ml. Microplates were incubated at 37°C for 20 hours without shaking. MIC was defined as the lowest concentration of an antibiotic where MRSA cannot grow.
Population Analysis
Population analysis of clinically isolated MRSA (22 strains) and MSSA (5 strains) was done by the established method [2] . An overnight culture of MRSA and MSSA strains was diluted with fresh medium to the appropriate bacterial density and spread onto a MHA plate containing serial twofold dilutions of imipenem with or without cyslabdan (20 m g/ml). The plates were incubated at 37°C for 20 hours. MIC 50 and MIC 90 were defined as the concentration at which 50 and 90% of the strains could not grow, respectively. b b-Lactamase Test For b-lactamase activity test, MRSA K24 was cultured in MHB at 37°C for 20 hours without shaking and adjusted to 1ϫ10 8 CFU/ml. After MHB was added to each well of a 96-well microplate in the absence or presence of cyslabdan (final concentration of 10 mg/ml), the inoculum was added at a concentration of 1ϫ10 7 CFU/ml. Nitrocefin (Carbiochem, final 25 mg/ml) was then added to the cultures. Microplates were incubated at 37°C for 120 minutes without shaking. b -Lactamase inactivated nitrocefin by the ring cleavage, resulting in a color change from yellow to red.
Other Antimicrobial Assays
Antimicrobial activity against 15 species of microorganisms was measured by the paper disk method. Media for microorganisms were as follows: GAM agar (Nissui Seiyaku) for B. fragilis; Bacto PPLO agar (Difco) supplemented with horse serum 15%, glucose 0.1%, phenol red 0.25% and agar 1.5% for A. laidlawii; nutrient agar (Difco) for the other bacteria; a medium composed of glucose 1.0%, yeast extract 0.5% and agar 0.8% for fungi and yeasts. A paper disk (6 mm i.d., Advantec) containing 10 m g of sample was placed on an agar plate. Bacteria except X. oryzae were incubated at 37°C for 24 hours. Yeasts and X. oryzae were incubated at 27°C for 24 hours. Fungi were incubated at 27°C for 48 hours. Antimicrobial activity was expressed as diameter (mm) of the inhibitory zone.
Results
Antimicrobial Activity of Cyslabdan
First, antimicrobial activity of cyslabdan was tested by the paper disk method. At the concentration of 10 m g/disk, cyslabdan showed no inhibition against 15 microorganisms including MSSA as described in Materials and Methods. Furthermore, the compound did not inhibit the growth of MRSA K24 at the same condition.
Next, anti-MRSA K24 strain activity of cyslabdan was tested by the liquid microdilution method [2] . Cyslabdan showed weak anti-MRSA activity with an MIC of 64 mg/ml.
Potentiation of Imipenem Activity against MRSA by Cyslabdan
By the paper disk assay, cyslabdan alone showed no anti-MRSA activity at 10 mg/disk disk, but showed potent anti-MRSA activity with inhibition zone of 27 mm on MHA plates containing imipenem (10 m g/ml). Then, the potentiating effect of cyslabdan on the activity of imipenem and other typical antibiotics against MRSA was investigated by the liquid microdilution method. The concentration of cyslabdan was set up at 10 mg/ml for these experiments. As summarized in Table 1 , cyslabdan markedly reduced the MIC value of imipenem from 16 to 0.015 m g/ml, yielding over 1000-fold potentiation of the activity. However, anti-MRSA activity of other typical antibiotics such as streptomycin, vancomycin, tetracyclin and ciplofloxacin was not enhanced by cyslabdan (Table 1) .
Population Analysis
To further substantiate the effect of cyslabdan, population analysis was also performed by using clinically isolated MRSA strains and MSSA strains with imipenem in the presence and absence of cyslabdan (20 m g/ml). The MIC range, MIC 50 and MIC 90 values are shown in Table 2 . The MIC 50 of imipenem against MRSA strains decreased from 32 to 0.25 mg/ml in combination with cyslabdan, indicating most clinically isolated MRSA become 128-fold sensitive to imipenem with cyslabdan. whereas, the MIC 50 of imipenem against MSSA strains showed no change even in the presence of cyslabdan. Thus, cyslabdan was found to affect only MRSA strains.
Potentiation of b b-Lactam Activity against MRSA by Cyslabdan
Cyslabdan was found to potentiate imipenem activity against MRSA. Therefore, it was tested whether or not the activity of other b-lactams including penams (penicillin G, ampicillin, and cloxacillin), cephems (cefalexin, cefmetazole and cefotaxime), and carbapenems (imipenem, panipenem and meropenem) was potentiated by the compound. As shown in Table 3 , cyslabdan potentiated the activity of all the b -lactams tested. In particular, carbapenems are most strongly potentiated (128ϳ1024-fold) by cyslabdan among the b-lactams.
Effect of Cyslabdan on Staphylococcal b b-Lactamase
Activities MRSA K24 was found to produce b-lactamase, because the color of nitrocefin changed from yellow to red by incubation with the strain. First, it was tested whether or not cyslabdan was degraded by b-lactamase of the MRSA K24. By the HPLC analysis cyslabdan was found to be stable by HPLC after the compound was incubated with MRSA K24. When MRSA K24 was incubated with nitrocefin and cyslabdan, the color was changed from yellow to red. Therefore, cyslabdan showed no effect on blactamase activity or b -lactamase production of MRSA K24.
Discussion
Cyslabdan, a new actinomycete metabolite, was found to potentiate imipenem activity against MRSA K24. Although cyslabdan itself showed very weak anti-MRSA activity with an MIC value of 64 mg/ml, the compound (10 mg/ml, no effect on MRSA) synergistically enhanced the imipenem activity against MRSA, decreasing the MIC value from 16 to 0.015 m g in combination with cyslabdan (Table 1) . Furthermore, the imipenem potentiating activity by cyslabdan was not limited to MRSA K24 strain, and effective to most MRSA strains clinically isolated (Table  2) . However, the activity of other typical antibiotics against MRSA was not enhanced by cyslabdan (Table 1) . Cyslabdan potentiated carbapenem activity against MRSA K24 most strongly among b-lactams (Table 3) . MRSA K24 strain produced b-lactamase. Cyslabdan did not inhibit the b -lactamase and the b -lactamase could not hydrolyse imipenem. Therefore, carbapenem activity against MRSA was more effectively enhanced by cyslabdan than other blactams (Table 3) . Anyway, carbapenem is the strongest antibiotic in the field of b -lactams, but the cost of the production is still expensive. Accordingly, our idea of drug discovery in this study is important because such a potentiator would be applied for the decrease of the dose of these types of antibiotics. Several compounds have been reported to potentiate blactam activity against MRSA; polyoxotungstates [3] , polyphenols such as epigallocatechin gallate isolated from tea [4] , corilagin from Arctostaphylos uva-urs [5] and tellimagrandin I from rose red (Rosa canina) [5] and diterpenes such as totarol isolated from totara tree [6] , and synthetic MC-200,613 [7] . Among these compounds, the structures of totarol, MC-200,616 and a part of cyslabdan are labdane-type diterpenes. Therefore, the labdane part is responsible for the activity.
MC-200,616 was reported to attack the penicillin binding protein 2Ј (PBP2Ј) expressed by MRSA, a strain insensitive to b -lactams and producing b -lactamase [7] . Our preliminary study on the mechanism of action suggested that cyslabdan showed no binding to PBP2Ј (data not shown) and showed no effect on PBP2Ј expression (data not shown) and b -lactamase activity, although cyslabdan shares a similar labdan skeleton with MC-200,616. Further studies on the mechanism of action are now in progress.
